Michael Barbella, Managing Editor01.16.24
The Medical Device Innovation Consortium (MDIC)'s Board of Directors has a new leader.
Chip Hance has assumed a two-year board chair term from outgoing chair Dr. Jijo James, chief medical officer, MedTech and External Innovation at Johnson and Johnson.
“I am grateful for Jijo’s visionary leadership as chairman to advance MDIC’s mission,” MDIC President/CEO Andrew Fish said. “Chip is a passionate champion of the value of medical device innovation to improve and save lives, and I look forward to working with him to continue elevating MDIC’s thought leadership and impact.”
Hance is currently CEO of Regatta Medical, a private equity investment partnership with GTCR. Regatta builds specialty technology companies with unique relevance to the medical device industry. A 35-year industry veteran of cardiovascular, diabetes and diagnostics devices, Hance has long served as the primary MDIC champion of the Early Feasibility Studies program. Previously Hance was CEO of Creganna Medical, Entrepreneur-in-Residence at CDRH, and president of Abbott Vascular, the cardiovascular device division of Abbott.
“I am humbled by the opportunity to serve as chair of the MDIC Board of Directors,” Hance said. “I have been involved with MDIC since its inception and look forward to driving even greater impact of MDIC’s essential work in accelerating medical device innovation and patient access. My priorities as board chair include expanding our membership base, especially among small and mid-sized manufacturers, and expanding adoption of MDIC’s programs in the medical technology ecosystem.”
MDIC advances the scientific and technical disciplines that are fundamental to medical technology throughout the total product lifecycle. Founded in 2012, MDIC is the premier public-private partnership convening medical device manufacturers, researchers, regulators, payers, patients, and health care providers as trusted collaborators to solve the industry’s complex challenges. Its impact is driving advancements in medical technology development, approval, coverage, adoption, and patient access in the core areas of quality design and manufacturing, evidence generation, digital health, and patient engagement.
Chip Hance has assumed a two-year board chair term from outgoing chair Dr. Jijo James, chief medical officer, MedTech and External Innovation at Johnson and Johnson.
“I am grateful for Jijo’s visionary leadership as chairman to advance MDIC’s mission,” MDIC President/CEO Andrew Fish said. “Chip is a passionate champion of the value of medical device innovation to improve and save lives, and I look forward to working with him to continue elevating MDIC’s thought leadership and impact.”
Hance is currently CEO of Regatta Medical, a private equity investment partnership with GTCR. Regatta builds specialty technology companies with unique relevance to the medical device industry. A 35-year industry veteran of cardiovascular, diabetes and diagnostics devices, Hance has long served as the primary MDIC champion of the Early Feasibility Studies program. Previously Hance was CEO of Creganna Medical, Entrepreneur-in-Residence at CDRH, and president of Abbott Vascular, the cardiovascular device division of Abbott.
“I am humbled by the opportunity to serve as chair of the MDIC Board of Directors,” Hance said. “I have been involved with MDIC since its inception and look forward to driving even greater impact of MDIC’s essential work in accelerating medical device innovation and patient access. My priorities as board chair include expanding our membership base, especially among small and mid-sized manufacturers, and expanding adoption of MDIC’s programs in the medical technology ecosystem.”
MDIC advances the scientific and technical disciplines that are fundamental to medical technology throughout the total product lifecycle. Founded in 2012, MDIC is the premier public-private partnership convening medical device manufacturers, researchers, regulators, payers, patients, and health care providers as trusted collaborators to solve the industry’s complex challenges. Its impact is driving advancements in medical technology development, approval, coverage, adoption, and patient access in the core areas of quality design and manufacturing, evidence generation, digital health, and patient engagement.